Over 100,000 individuals in the United States are currently in need of organ transplants. The demand for organs, such as hearts, kidneys, and livers, far exceeds the available supply and people sometimes wait years to receive a donated organ.
Investigators from Cedars-Sinai; the University of California, San Francisco (UCSF); Harvard University; and the Weizmann Institute of Science in Israel conducted a study to determine where individual nutrients are absorbed in the small intestine. For the first time, they identified the molecular markers that define five distinct intestinal regions.
The Wake Forest Institute for Regenerative Medicine (WFIRM) is the recipient of an inaugural U.S. National Science Foundation (NSF) Engines Program award. The NSF Engines: Piedmont Triad Regenerative Medicine Engine is a regional project that provides an innovation ecosystem to stimulate workforce development, job creation, and economic growth through the development of technologies that benefit the emerging industry.
Building upon the success of its previous REU program (Award #1659663, 2018-2022), WFIRM’s renewed grant has a specific focus on growing the increasing the engagement of underrepresented minority groups, women, and non-traditional students, including students attending 2- and 4-year universities.
Irvine, Calif., Oct. 26, 2023 — A study from the University of California, Irvine has revealed that in 2022, 38 North American businesses used direct-to-consumer advertising to promote unproven stem cell interventions and exosome products as purported treatments and preventatives for COVID-19. Collectively, these organizations operated or facilitated access to 60 clinics – with 24 in the U.
Generating specific cell lineages from induced pluripotent stem cells and embryonic stem cells is the holy grail of regenerative medicine.
The grant opportunity will create a continued impact on the rate of clinical translation for regenerative medicine therapies and the commercialization of regenerative medicine products within the global market.
Brinter Bio-Implant company joined the RegeneratOR’s Innovation Accelerator in 2023, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter, in Winston-Salem.
It’s a beautiful moniker, but for the world’s butterfly children’ it belies a devastating reality filled with enormous pain and suffering caused by a rare skin condition – Epidermolysis Bullosa (EB).
Tissue engineering research has shown that a skin cell type could be a new therapeutic target to accelerate the healing of burns and possibly other wounds.
The Wake Forest Institute for Regenerative Medicine (WFIRM) will make history this month when the first bioprinted solid tissue constructs soar to the International Space Station (ISS) on board the next all private astronaut mission by commercial space leader Axiom Space.
Institute, including three new centers, will lead research to foster novel discoveries and explore new treatments for a range of diseases from leukemia to Alzheimer’s disease.
The Regenerative Medicine Hub continues to grow and attract top talent with the addition of Ron Hann, PhD, a former senior level official with the Department of Defense.
Immunaeon is the latest addition to the RegeneratOR’s Innovation AcceleratOR, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem.
Technology that can change skin tissue into blood vessels and nerve cells also shows promise as a treatment for traumatic muscle loss.
Pioneering heart care is a tradition at Cedars-Sinai. It’s a tradition that took root in 1924, when Cedars-Sinai became home to the first electrocardiogram machine in Los Angeles.
MIMEDX is the latest addition to the RegeneratOR Innovation Accelerator, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem.
RTT Medical is the newest tenant of the Innovation Accelerator, a support ecosystem created by the RegenMed Development Organization (ReMDO) to help companies with new or emerging regenerative medicine technologies speed up the translation of products to patients.
Eliksa Therapeutics, a regenerative medicine company developing novel therapeutics for a range of debilitating diseases, announced today it has launched with investments from the University of Utah (U) and Militia Hill Ventures (MHV) to develop and commercialize multiple clinical programs using the regenerative medicine technology developed at the U.
• Just like the real thing. The stem cell–derived interneurons, which play a role in sensations like touch and pain, are indistinguishable from their real-life counterparts in the body.
• Tomorrow’s therapies. In addition to potential treatments for injury-related sensation loss, the discovery could lead to new methods for screening drugs for chronic pain.
• Moving forward. While stem cells from mice were used in the research, scientists are now working to replicate the findings with human cells.
Osteoarthritis – a painful condition that results from the deterioration of the cartilage in our joints – affects millions of people worldwide. To combat this issue, NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment for this common condition.
Two recent discoveries co-led by scientists at Cedars-Sinai may help lead to new ways to treat patients with Allan-Herndon-Dudley syndrome (AHDS), a brain development disorder that causes severe intellectual disability and problems with movement.
The 2022 Annual Report from the Smidt Heart Institute at Cedars-Sinai is available now, detailing the latest research and medical achievements by the expert team ranked No. 1 for cardiology and cardiac surgery in California by U.S. News & World Report.
More than four times as many businesses and clinics than were identified in 2016 are selling stem cell products not approved by the U.S. Food and Drug Administration and lack convincing evidence of safety and efficacy, according to a five-year study conducted by University of California, Irvine Program in Public Health professor of health, society and behavior Leigh Turner. The analysis appears online in the journal Cell Stem Cell.
The American Medical Society for Sports Medicine (AMSSM) has released a position statement on Principles for the Responsible Use of Regenerative Medicine in Sports Medicine.
The University of California, Irvine has received a five-year, $5 million award from the California Institute for Regenerative Medicine to support a comprehensive doctoral, postdoctoral and clinical researcher training program to prepare the current and next generation of leaders in stem cell biology, gene therapy and regenerative medicine.
Regenerative medicine has enormous implications for treatment and prevention of chronic pain including conditions like osteoarthritis, diabetic and peripheral neuropathy, and even spinal cord injuries and degenerative disk disease. According to one expert, there is potential to “[turn] back the time clock.”
With the recent announcement of the RegeneratOR Test Bed to support regenerative medicine start up companies, the Wake Forest Institute for Regenerative Medicine (WFIRM) and the RegenMed Development Organization (RemDO) are embarking on the next step – to help create the future workforce.
Phase Holographic Imaging is collaborating with the RegeneratOR Test Bed, a new regenerative medicine endeavor in North Carolina, by providing its technology to help support start-up companies in the regenerative medicine space.
The RegenMed Development Organization (ReMDO), a non-profit foundation headquartered in Winston-Salem, NC, and dedicated to advancing the regenerative medicine field nationwide, and the Wake Forest Institute for Regenerative Medicine (WFIRM), the largest regenerative medicine institute in the world, announce the launch of the RegeneratOR Test Bed.
ACSM’s comprehensive sports medicine and exercise science conference takes place virtually from June 1 to 5 with programming covering the science, practice, public health and policy aspects of sports medicine, exercise science and physical activity.
The 2021 Virtual ACSM Basic Science World Congress focuses on regenerative medicine. Chaired by Marcas M. Bamman, Ph.D., FACSM, from the University of Alabama at Birmingham, this world congress brings together researchers to discuss cutting-edge science in this rapidly developing field.
Gain story ideas and learn about cutting-edge science at ACSM’s comprehensive sports medicine and exercise science conference that covers the science, practice, public health and policy aspects of sports medicine, exercise science and physical activity.
In a lab on the upper floors of Engineering Hall, something is growing. It’s not a plant. And it’s not an animal. What Ronke Olabisi is growing in her lab is us. From new skin and retinal tissue to hearts and livers, she’s developing the tools to rebuild and repair the human body. A UCI assistant professor of biomedical engineering, Olabisi has been working with regenerative tissue for the better part of seven years, using a hydrogel based on polyethylene glycol diacrylate.
Irvine, Calif., May 5, 2021 – If you haven’t had knee surgery, you may have a friend or relative who has. But do you know anyone who has had an operation on their jaw? Although the temporomandibular joint is crucial to speaking, chewing and even breathing, treatments for TMJ disorders are far less common than those for the knee.
Difficult-to-treat, chronic wounds in preclinical models healed with normal scar-free skin after treatment with an acellular product discovered at Mayo Clinic. Derived from platelets, the purified exosomal product, known as PEP, was used to deliver healing messages into cells of preclinical animal models of ischemic wounds. The Mayo Clinic research team documented restoration of skin integrity, hair follicles, sweat glands, skin oils and normal hydration.
Ischemic wounds occur when arteries are clogged or blocked, preventing important nutrients and oxygen from reaching the skin to drive repair. This groundbreaking study titled, “TGF-β Donor Exosome Accelerates Ischemic Wound Healing,” is published in Theranostics.
As regenerative therapies for blinding diseases move closer to clinical trials, the National Eye Institute’s functional imaging consortium, a part of the NEI Audacious Goals Initiative (AGI), is pioneering noninvasive technologies to monitor the function of the retina’s light-sensing neurons and their connections to the brain.
Injecting hydrogels containing stem cell or exosome therapeutics directly into the pericardial cavity could be a less invasive, less costly, and more effective means of treating cardiac injury.
The American Institute for Medical and Biological Engineering (AIMBE) has elected to its College of Fellows Evan Y. Snyder, M.D., Ph.D., professor and founding director of the Center for Stem Cells and Regenerative Medicine at Sanford Burnham Prebys Medical Discovery Institute. Snyder was nominated, reviewed, and elected by his peers and members of the College of Fellows for his seminal contributions to regenerative medicine.
Leaders in stem cell science and regenerative medicine will combine two separate courses into one in June 2021.
Leaders in stem cell science and regenerative medicine will combine two separate courses into one in June 2021.
UCLA researchers are the first to create a version of COVID-19 in mice that shows how the disease damages organs other than the lungs. Using their model, the scientists discovered that the SARS-CoV-2 virus can shut down energy production in cells of the heart, kidneys, spleen and other organs.
A team at Aalto University has used bacteria to produce intricately designed three-dimensional objects made of nanocellulose. With their technique, the researchers are able to guide the growth of bacterial colonies through the use of strongly water repellent – or superhydrophobic – surfaces.
A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of MCO1. The company is planning a U.S. clinical trial for later this year.
The American Academy of Orthopaedic Surgeons (AAOS) continues to demonstrate its commitment to advancing the quality of musculoskeletal care in a fully transparent and scientific way. Debuting today as a new member benefit, the AAOS Biologics Dashboard is a dynamic online tool designed to help orthopaedic surgeons navigate the approval status of biologic-based interventions. The development of the AAOS Biologics Dashboard is just one of several efforts within the Academy’s Biologics Initiative that offers evidence-based guidance to the musculoskeletal health community. An additional effort is the revision of two biologics-related position statements, recently approved by the AAOS Board of Directors.
Research in pigs shows that using the exosomes naturally produced from a mix of heart muscle, endothelial and smooth muscle cells — all derived from human induced pluripotent stem cells — yields regenerative benefits equivalent to the injected human induced pluripotent stem cell-cardiac cells.
Imagine this: A patient learns that they are losing their sight because an eye disease has damaged crucial cells in their retina. Then, under the care of their doctor, they simply grow some new retinal cells, restoring their vision.
Although science hasn’t yet delivered this happy ending, researchers are working on it – with help from the humble zebrafish. When a zebrafish loses its retinal cells, it grows new ones. This observation has encouraged scientists to try hacking the zebrafish’s innate regenerative capacity to learn how to treat human disease. That is why among the National Eye Institute’s 1,200 active research projects, nearly 80 incorporate zebrafish.
Scientists at Sanford Burnham Prebys, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore in Rome have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring. The study, published in EMBO Reports, reveals a promising new therapeutic approach for Duchenne muscular dystrophy (DMD), an incurable muscle-wasting condition.
The National Institutes of Health has renewed a five-year grant for $5 million for the Alliance for Regenerative Rehabilitation and Training (AR3T) to continue its work expanding scientific knowledge, expertise and methodologies focused on science and regenerative medicine.
WFIRM scientists were able to show that bioengineered uteri in an animal model developed the native tissue-like structures needed to support normal reproductive function.